Programmed death-1 (PD-1) is involved in T-cell tolerance to self-antigens. For some cancers, it has been suggested that the expression of a ligand of PD-1, namely PD-L1, could contribute to tumor escape from immune destruction. Nevertheless, the relationship between PD-1 expression on tumor-infiltrating T lymphocytes (TILs), disease stage, and TIL responsiveness is still poorly documented. In this study, we show that freshly isolated CD4+ and CD8+ TILs express substantial levels of PD-1 in primary melanomas. The expression of PD-1 was further increased at later stages in distant cutaneous metastases, especially on CD8+ TILs. The expression of PD-1 ligands was frequent only in metastases, on both tumor cells and tumor-derived myeloid cells....
BackgroundRecent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed...
Immune checkpoint inhibition with anti-PD-1 and anti-CTLA-4 monoclonal antibodies has revolutionised...
Purpose: Infusion of highly heterogeneous populations of autologous tumor-infiltrating lymphocytes (...
Programmed death-1 (PD-1) is involved in T-cell tolerance to self-antigens. For some cancers, it has...
Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary and acquired...
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durab...
International audienceDespite its negative regulatory role on tumor specific T cells, PD-1 is also a...
Recent studies have indicated that therapeutic antibodies targeting PD-L1 show remarkable efficacy i...
Immune checkpoint inhibitors blocking the interaction between programmed death-1 (PD-1) and PD-1 lig...
The programmed death 1 (PD-1) receptor is a negative regulator of activated T cells and is up-regula...
Immune checkpoint inhibition has resulted in dramatic improvements in overall and relapse-free survi...
Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rates...
SummaryTherapeutic antibodies targeting programmed cell death 1 (PD-1) activate tumor-specific immun...
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T lympho...
Background: Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with syste...
BackgroundRecent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed...
Immune checkpoint inhibition with anti-PD-1 and anti-CTLA-4 monoclonal antibodies has revolutionised...
Purpose: Infusion of highly heterogeneous populations of autologous tumor-infiltrating lymphocytes (...
Programmed death-1 (PD-1) is involved in T-cell tolerance to self-antigens. For some cancers, it has...
Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary and acquired...
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durab...
International audienceDespite its negative regulatory role on tumor specific T cells, PD-1 is also a...
Recent studies have indicated that therapeutic antibodies targeting PD-L1 show remarkable efficacy i...
Immune checkpoint inhibitors blocking the interaction between programmed death-1 (PD-1) and PD-1 lig...
The programmed death 1 (PD-1) receptor is a negative regulator of activated T cells and is up-regula...
Immune checkpoint inhibition has resulted in dramatic improvements in overall and relapse-free survi...
Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rates...
SummaryTherapeutic antibodies targeting programmed cell death 1 (PD-1) activate tumor-specific immun...
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T lympho...
Background: Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with syste...
BackgroundRecent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed...
Immune checkpoint inhibition with anti-PD-1 and anti-CTLA-4 monoclonal antibodies has revolutionised...
Purpose: Infusion of highly heterogeneous populations of autologous tumor-infiltrating lymphocytes (...